Teva Pharmaceutical Industries (TEVA) Gross Profit (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Gross Profit for 18 consecutive years, with $2.2 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Gross Profit rose 2.43% year-over-year to $2.2 billion; the trailing twelve-month figure through Jun 2026 stood at $9.1 billion (up 10.15% YoY), and the FY2025 full-year result was $8.9 billion, up 10.84% from the prior year.
• Gross Profit climbed to $2.2 billion in Q2 2026 per TEVA's latest filing, from $2.0 billion in the prior quarter.
• Across five years, Gross Profit topped out at $2.7 billion in Q4 2025 and bottomed at $1.6 billion in Q1 2023.
• Historically, Gross Profit has averaged $2.0 billion across 5 years, with a median of $1.9 billion in 2025.
• The sharpest annual moves came in 2022 and 2023: Gross Profit slipped 13.66% in 2022, then surged 36.5% in 2023.
• Over 5 years, Gross Profit stood at $1.8 billion in 2022, then surged by 36.5% to $2.4 billion in 2023, then declined by 12.21% to $2.1 billion in 2024, then rose by 25.22% to $2.7 billion in 2025, then declined by 18.94% to $2.2 billion in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $2.2 billion, $2.0 billion, and $2.7 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.